Curasight

Quick facts

Phase 2 pipeline

• 64Cu-DOTA-AE105 · Oncology
  Somatostatin receptor targeting

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Curasight portfolio CI brief
• Curasight pipeline updates RSS